AUTHOR=Liu Mingyue , Xu Chang , Qin Xiaochun , Liu Wenwu , Li Deping , Jia Hui , Gao Xudong , Wu Yuting , Wu Qiong , Xu Xiangbo , Xing Bo , Jiang Xiaowen , Lu Hongyuan , Zhang Yingshi , Ding Huaiwei , Zhao Qingchun TITLE=DHW-221, a Dual PI3K/mTOR Inhibitor, Overcomes Multidrug Resistance by Targeting P-Glycoprotein (P-gp/ABCB1) and Akt-Mediated FOXO3a Nuclear Translocation in Non-small Cell Lung Cancer JOURNAL=Frontiers in Oncology VOLUME=12 YEAR=2022 URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.873649 DOI=10.3389/fonc.2022.873649 ISSN=2234-943X ABSTRACT=
Multidrug resistance (MDR) is considered as a primary hindrance for paclitaxel failure in non-small cell lung cancer (NSCLC) patients, in which P-glycoprotein (P-gp) is overexpressed and the PI3K/Akt signaling pathway is dysregulated. Previously, we designed and synthesized DHW-221, a dual PI3K/mTOR inhibitor, which exerts a remarkable antitumor potency in NSCLC cells, but its effects and underlying mechanisms in resistant NSCLC cells remain unknown. Here, we reported for the first time that DHW-221 had favorable antiproliferative activity and suppressed cell migration and invasion in A549/Taxol cells